tbuckley/cabot-search huggingface dataset:
Tumor-informed assessment of molecular residual disease and its incorporation into practice for patients with early and advanced-stage colorectal cancer (CRC-MRD Consortia).
Authors: Pashtoon Murtaza Kasi, Farshid Dayyani, Van K. Morris, Scott Kopetz, Aparna Raj Parikh, Jason Scott Starr, Stacey Cohen, Axel Grothey, Christopher Hanyoung Lieu, Mark H. O'Hara, Kate Loranger, Laura Westbrook, Shruti Sharma, Shifra Krinshpun, Nicole Hook, Bernhard Zimmermann, Paul R. Billings, Alexey Aleshin
Journal: Journal of Clinical Oncology (2020)

4108 Background: Circulating tumor DNA (ctDNA) testing can be used for the assessment of molecular residual disease (MRD) in patients with early-stage or advanced colorectal cancer (CRC). Prospective evaluation of this methodology in clinical practice has been limited to-date. Methods: A personalized and tumor-informed multiplex PCR assay (Signatera 16-plex bespoke mPCR NGS assay) was used for the detection and quantification of ctDNA for MRD assessment. We analyze and present results from an ongoing early adopter program of ctDNA testing across the spectrum of CRC management. Results: Here we present a total of 250 patients with colon (n=200), rectal (n=40), and other lower gastrointestinal cancers (n =10; anal, appendiceal, small bowel). MRD positivity rates and ctDNA quantification (mean tumor molecules/mL) are shown in Table. ctDNA detection was significantly associated with stage of disease (p&lt;0.0001 Chi-square: 70.33). Additionally, in patients with radiologically measurable active metastatic disease, ctDNA detection rate was 100%. On the contrary, patients with advanced/metastatic disease who had partial response to treatment or no evidence of disease (NED) showed 28.5% and 19.2% of ctDNA-positivity, respectively. Conclusions: This is the first large, real-world study reporting on the results from a clinically validated MRD assay. For the first time we delineate MRD rates and quantify ctDNA concentration in patients with early-stage and advanced CRC. Furthermore, we provide an initial readout that effective ongoing treatment in patients with CRC may be correlated with ctDNA clearance. Ongoing analysis expanded to a cohort of 1200 clinical cases including correlation with genomic and serial testing will be presented. [Table: see text]
Perioperative hidden blood loss in aged patients with femoral intertrochanteric fracture
Authors: Shaohui Shi, Guoping Wu, Haizhao Wen, Baoxi Wang, Randong Wang
Journal: BMJ (2016)

Objective
To assess the perioperative hidden blood loss in aged patients with femoral intertrochanteric fracture.


Methods
Clinical data of 243 patients (111 males and 132 females) with intertrochanteric fracture admitted from 2009 September to 2015 September were retrospectively reviewed. Two hundred and seventeen patients aged 60-98 years received surgical treatment and 26 patients aged 62-91 years received conservative treatment (non-surgical group). In surgical group, 17 cases were operated within 1 d after fracture, 71 within 3 d, 73 within 7 d, 31 within 14 d, and 25 cases were operated after 14 d. Hidden blood loss was evaluated and blood routine was tested.


Results
The hidden blood loss was (340±216) ml in non-surgical patients, (602±216) ml in patients operated after 14 d, (671±327) ml in patients operated 8-14, (596±362) ml in patients operated 4-7 d, and (505± 119) ml in patients operated 2-3 d, (498±244) ml in patients operated within 1 d; there was significant difference among groups (F=14.758, P=0.001). The hemoglobin level in non-surgical group was (121.8±17.6) g/L within 1 d after fracture, (101.1±23.3) g/L on 1-3 d, (91.5±31.9) g/L on 4-7 d, (92.2±31.6) g/L on 8-14 d, and (108.3±22.4) g/L after 14 d; there was statistically significant among groups (F=12.457, P=0.001).


Conclusions
Hemoglobin level in elderly patients with femoral intertrochanteric fracture is dynamically changed, and reaches the lowest point within 1-2 weeks after injury; and operation is an important factor of hidden blood loss in femoral intertrochanteric fracture patients.


Key words: 
Hip fractures; Perioperative care; Hemoglobins; Blood loss, surgical; Hidden blood loss
Pathological outcomes of HER2-positive early breast cancer patients treated with neoadjuvant trastuzumab or dual anti-HER2 therapy and carboplatin with docetaxel: A Maria Sklodowska-Curie National Research Institute of Oncology experience.
Authors: Agnieszka I. Jagiello-Gruszfeld, Izabela Lemanska, Renata Sienkiewicz, Ewa Szombara, Roman Dubianski, Elzbieta Brewczynska, Katarzyna Pogoda, Aleksandra Konieczna, Michal Kunkiel, Anna Majstrak-Hulewska, Wojciech P Olszewski, Anna Niwinska, Zbigniew Nowecki
Journal: Journal of Clinical Oncology (2020)

e12655 Background: Pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) for breast cancer predicts the risk of recurrence and increasingly may indicate the need for additional therapy postoperatively. Methods: A retrospective analysis was performed in two cohorts of patients (pts) treated with docetaxel, trastuzumab and carboplatin (TCH) or with docetaxel, carboplatin and dual blockade (TCH-P) in the neoadjuvant setting in patients with early breast cancer (tumor size &lt; 50 mm and &gt; 10 mm and cN0 or cN1) in our Clinic, and who had definitive surgery was conducted. Demographic data, size, grade, tumor type, receptor status prior to neoadjuvant treatment, pathological complete response (pCR) rates, and adverse effects were analyzed. The pCR was defined as ypT0 ypN0. Results: Patient in cohort A (n = 58) received TCH x 6 cycles and in cohort B (n = 25) TCH-P x 6 cycles. Median age was 51 (range 23 to 76 years) in cohort A and 46 (range: 30-68) in cohort B. In cohort A 37 (64%) of pts was HR-positive, in cohort B only 9 (36%) pts . The most common adverse events in both groups were neutropenia, diarrhea, chemotherapy induced polyneuropathy and febrile neutropenia. There are no significant differences in the frequency of adverse events in two cohorts. There was no symptomatic heart failure, but 6 pts (10%) in cohort A and 5 pts (16%) in cohort B had &gt; 10% asymptomatic decrease in LVEF. All patients were evaluable for pCR. Higher rates of pCR were achieved in the HER2pos/HRneg pts: 66% (n = 14) in cohort A, and 87% (n = 14) in cohort B. In group HER2pos/HRpos pts, the pCR rate was 48% (n = 18) vs 55% (n = 5) respectively. Conclusions: In HER2positive early breast cancer, a dual blockade (trastuzumab and pertuzumab) together with carboplatin and docetaxel neoadjuvant chemotherapy achieved higher rates of pCR ( 76%) compared with pts treated with trastuzumab, carboplatin and docetaxel (56%). However, a much higher percentage of pCR was observed in the group of patients with non-luminal cancers, who received a double blockade (87% vs 66%).
难以缓解的腹痛
Authors: 曾昭耆
Journal: BMJ (2006)

女性患者,56岁,左下腹隐痛约半年,妇科指检发现左侧肿块,B超见左侧卵巢囊实性包块,约鸭蛋大.临床诊断左侧卵巢癌,即决定行手术治疗.术中证实为卵巢囊实性癌,活检冰冻切片显示分化不佳,故进行了双侧卵巢、输卵管、子宫及大网膜切除.因发现部分淋巴结有转移,所以经治医生安排其高蛋白饮食,迫切希望患者加强营养,以便尽早开始化疗.但患者进食后持续腹胀腹痛.先后给予几种助消化药、解痉挛药及促胃肠蠕动药,并由护士搀扶散步,均无缓解,腹痛反而加重,故请内科会诊。
警惕耳石症引起的头晕
Authors: 周涛
Journal: BMJ (2010)

患者女,68岁,2010年2月4日因颈椎病阵发头晕2年余,来站要求行耳针治疗.1周后复诊,症状改善不明显.于是详细追问病史,患者2年前因晨起后头晕就诊于某医院,经检查有颈椎病,住院给予中西医等多种方法治疗近半个月,未见明显好转,遂出院.2年中断断续续反复头晕,入睡、晨起时明显,发作时会有眩晕,无耳鸣、耳聋,重时引起呕吐,午后头晕症状可减轻或消失,也就未采取任何治疗措施.今年头晕加重,头部转动也发生眩晕,遂考虑试用耳针治疗.体检:体温36.5 ℃,脉搏72次/min,呼吸18次/min,血压124/80 mm Hg(16.5/10.6 kPa),神志清楚,颈软无抵抗,心肺腹部无异常.躺下、坐起可导致患者眩晕复发。
A new prognostic and predictive tool to enhance shared decision making in stage III colon cancer.
Authors: Alberto F. Sobrero, Alberto Puccini, Qian Shi, Axel Grothey, Thierry Andre, Anthony Frank Shields, Marcello Ceppi, Paolo Bruzzi
Journal: Journal of Clinical Oncology (2020)

4010 Background: Survival outcomes in patients with stage III colon cancer varies widely according to T-N sub-stages. The ability to estimate the benefit of each therapeutic option (surgery alone, fluoropyrimidines alone, oxaliplatin-based doublet for either 3 or 6 months) in each T-N subgroup within stage III, may provide more accurate information helping doctors and patients in the complex shared decision-making process surrounding adjuvant therapy. Methods: Theoutcomedata of 12,834 patients with stage III colon cancer enrolled in the IDEA trial served as our database. Patients were categorized in 16 sub-stages, based on the T-N categories. We created a meta-regression model to predict the expected 3-year DFS within each T-N sub-stage and hence the 5-year DFS rates were projected. We then evaluated the efficacy of each therapeutic option in every sub-stage, working backward by subtraction, using an average of the HRs reported in the pertinent trials publication as conversion factor. Results: Large differences in 3-year DFS rate were observed among the subgroups, ranging from 95% (T1N1a) to 29% (T4N2b) in the overall population. The contribution to outcome of each therapeutic option in this setting varied widely across sub-stages. According to our model, patients with T1N1a cancers have a projected 5-year DFS of 85% with surgery alone. Adjuvant fluoropyrimidine alone results in 4.2% absolute DFS gain; an additional 1.7% and 0.6% gain is seen with oxaliplatin for 3 and 6 months, respectively. Patients with T4N2b cancers show a 4.7% 5-year DFS with surgery alone, and a 7.1%, 5.0%, 2.1% increase with the aforementioned adjuvant options, respectively. Conclusions: The resulting overlay bar graph gives patients and doctors the projected relative benefit of each treatment option and may substantially help the shared decision-making process.
Current status and strategies in public training of cardiopulmonary resuscitation at home and abroad
Authors: Liyun Wang, Lizheng Fang, Wenhua Zhu
Journal: BMJ (2020)

Cardiopulmonary resuscitation (CPR) training plays an important role in improving the survival rate of patients with out-of-hospital cardiac arrest, and attention should be paid to the knowledge education and skill training of CPR for the public. This article reviews the current situation of CPR training at home and abroad, and puts forward suggestions for CPR training in China, particularly emphasizes that CPR training should be included in the compulsory education and that general practitioners should play a leading role in public CPR training.


Key words: 
Cardiopulmonary resuscitation; Training; Present situation
Annual lung cancer screening by chest X ray to avoid further examinations.
Authors: Tatsuo Kimura, Shinya Fukumoto, Hideki Fujii, Akemi Nakano, Yuji Nadatani, Yukie Tauchi, Tomohiro Suzumura, Koichi Ogawa, Tomoya Kawaguchi, Norifumi Kawada
Journal: Journal of Clinical Oncology (2020)

e19124 Background: Chest X ray (CXR) has been the most common screen procedure for detection of lung cancer. However, if patients had old inflammatory shadows such as tuberculosis, calcification and fibrotic changes, it would become increasingly difficult to detect the lung cancer. In that case, a comparative review of the CXR to the previous one helps the detection of new shadows. We examined whether the repeat participants (pts) who received the medical checkup annually, may have a profit for the lung cancer detection screening. Methods: Our clinic “MedCity21” is a university outpatient clinic to undergo a complete medical checkup in private health screening program. The pts with abnormalities detected in CXR were announced by call request and invited to our specialty clinic for chest CT scan as further examination. We examined the varieties of abnormal shadows by CXR and CT scans, and compared the differences between the repeat and the first-time pts using the chi-square tests, in 2018 and 2019 respectively. Results: In 2018, a total of 12540 with repeat / first-time pts of 6898/5642 pts (55/45%) were enrolled. The CXR abnormalities requiring further examinations were a total of 335 (2.6%) with those of 138/188 pts (p &lt; 0.01). After the call requests, a total of 239 (71.3%) with those of 109/130 pts in 2018 received chest CT scan in our specialty clinic. In 2019, a total of 13690 pts with those of 7748/5942 (56.6/43.4%) were enrolled. The CXR abnormalities requiring further examinations were a total of 323 (2.4%) with those of 137/186 pts (p &lt; 0.01). After the call requests, a total of 224 (69.3%) pts with those of 104/120 pts received chest CT scan in our specialty clinic. The varieties of abnormal shadows by CT scans showed that 8.3/20.8% (p &lt; 0.01) in 2018 and 11.5/21.7% (p = 0.04) in 2019 of old inflammatory shadows, 11.0/6.9% (p = 0.27) in 2018 and 14.4/1.7% (p &lt; 0.01) in 2019 of acute inflammatory shadows, respectively. The nodule was detected in 11.9/11.5% in 2018 and 8.7/10.8% in 2019 with no significant differences. Lung cancer was detected in 3/3 pts in 2018, and 1/3 pts in 2019. Conclusions: The repeat pts in each year, had significantly lower rate of CXR abnormalities detection, and had lower rate of the detection of old inflammatory changes as significant. In private health screening program, the repeat pts may have higher profits for the avoidance of further examination for lung cancer detection than the first-time pts.
间断腹痛-腹泻-停止排气排便
Authors: 蒋绚, 王秋实, 张学武, 王智峰, 刘玉兰
Journal: BMJ (2012)

患者男性,32岁,江西人,农民.因间断腹痛、腹泻及停止排气、排便2个月余,加重5d于2010年12月20日收入我院消化内科.患者于2010年10月初(约2个月前)无明显诱因出现腹痛,以中下腹为主,绞痛伴阵发性加重,伴有腹泻,大便为水样,未见黏液及脓血,4～5次/d,就诊于当地医院诊断为急性肠炎,予抗感染治疗2d后患者症状消失.后患者无明显诱因又出现2次明显腹痛、腹胀,伴恶心呕吐及腹泻,就诊于多家医院,腹部X线检查示肠管明显扩张积气伴数个气液平面,考虑诊断为肠梗阻.腹部CT提示腹腔、盆腔积液,胆囊结石,右侧升结肠区肠管异常改变,考虑结肠炎症改变、不完全除外肠套叠改变.数字全消化道 关键词：系统性红斑狼疮;假性肠梗阻
The risk factors of nocturnal hypoglycemia in elderly patients with type 2 diabetes
Authors: Xiao-ye He, Yu Hu
Journal: BMJ (2009)

This study was to evaluate the risk factors of nocturnal hypoglycemia in elderly patients with type 2 diabetes by continuous glucose monitoring system. Fifty-one type 2 diabetic patients aged 60 or above were enrolled and the episodes of nocturnal hypoglycemia were documented. The risk factors of nocturnal hypoglycemia were analyzed by logistic regression and the cut-off of glucose levels at bedtime for nocturnal hypoglycemia was evaluated. There were twenty-two patients with total 681 nocturnal hypoglycemic episodes. Logistic regression analysis showed that the lowest glucose level at bedtime was the risk factor of nocturnal hypoglycemia (OR=0.36, 95% CI:0.13-1.00, P<0.05), while the gender, age, diabetes duration, therapy regimen, the highest and average glucose levels at bedtime were not associated to nocturnal hypoglycemia. Receiver operating characteristic curve (ROC) showed that the bedtime glucose at≤6.2 mmol/L was the best cut-off point for predicting nocturnal hypoglycemia.

Key words: 
Diabetes mellitus, type 2;  Hypoglycemia
The progress of community-based manngement on coronary atherosclerotic heart disease
Authors: 钟益刚, 王宁夫
Journal: BMJ (2011)

随着医学模式逐渐从单纯的生物医学模式向生物-心理-社会医学模式的转变,高血压、心力衰竭、冠心病等慢性心血管病的治疗措施方面已逐渐将重心转移到疾病的社区防治和管理上来,从疾病本身、社会、心理多个角度加强对疾病的干预.有研究表明,包括健康教育、生活方式干预、心理干预等在内的社区综合干预措施可以降低冠心病的危险因素及发病率,减少冠心病患者的心血管事件的发生率、再入院率,降低死亡率,提高生活质量[1].现就冠心病的社区管理研究现况作一简述。
Cost-effectiveness of genomic profiling in veterans with metastatic lung adenocarcinoma.
Authors: Pradeep Poonnen, Olivia Dong, David Winski, Shelby D. Reed, Vishal Vashistha, Jill S. Bates, Michael J. Kelley, Deepak Voora
Journal: Journal of Clinical Oncology (2020)

7075 Background: Tumor profiling identifies patients who are eligible for targeted anticancer therapies. Common tumor profiling approaches include targeted gene panel testing (TGPT), which tests for common mutations in select genes, and multigene panel sequencing (MGPS), which tests for a broad range of mutations in a comprehensive set of genes. Our objective was to determine the lifetime cost-effectiveness of MGPS and TGPT compared to no tumor profiling for Veterans with metastatic lung adenocarcinoma from the Veterans Health Administration’s (VHA) perspective. Methods: A decision analytic model was developed to simulate outcomes for a closed cohort of hypothetical Veterans with metastatic lung adenocarcinoma considering anticancer therapy. OncoKB genes with levels of evidence 1 and 2 for guiding therapy were included. Three profiling strategies were studied: TGPT ( ALK, EGFR, ROS1), MGPS ( ALK, BRAF, EGFR, HER2, MET, NTRK1, NTRK2, NTRK3, RET, ROS1), and no tumor profiling. We assumed 95% of patients with actionable mutations received targeted therapies. Non-targeted therapy options included chemotherapy and/or immunotherapy, and no anticancer therapy. Model inputs were derived from randomized trials (progression-free survival), VHA and Medicare (drug costs), published studies (non-drug cancer-related management costs, health care utilities), and VHA National Precision Oncology Program and cBioPortal for Cancer Genomics databases (mutation prevalence). Costs (2019 US$) and quality-adjusted life years (QALYs) were discounted at 3%/year. Base-case scenario, one-way sensitivity analyses, and probabilistic sensitivity analyses (PSA) using 1,000 Monte Carlo simulations were completed. Results: Base-case results and corresponding 95% credible intervals from the PSA indicated the cost/QALY gained was $309,399 ($280,371-$343,161) for TGPT and $324,707 ($296,086-$359,778) for MGPS compared to no tumor profiling. Of the 3 strategies, MGPS resulted in the highest number of QALYs. One-way sensitivity analyses revealed the cost/QALY estimates were most impacted by changes in health state utility on a targeted therapy (quality of life), costs of alectinib, and non-drug cancer-related costs in patients receiving targeted therapy. Compared to no tumor profiling, cost-effectiveness ratios for both profiling approaches surpassed the $150,000/QALY threshold in 100% of PSA simulations. Conclusions: Tumor profiling (TGPT or MGPS) can optimize anticancer therapy selection in patients with metastatic lung adenocarcinoma and improve quality-adjusted survival, but compared to no tumor profiling, is not cost-effective.
A study on a standardized tertiary rehabilitation program in promoting activities of daily living in 1365 stroke patients
Authors: 脑血管病三级康复治疗方案研究课题组
Journal: BMJ (2007)

目的 探索规范三级康复治疗对于脑卒中偏瘫患者日常生活活动能力的影响.方法 采用大样本、多中心、前瞻性的随机对照研究方法.分别在各研究中心随机入选患者,按脑梗死和脑出血分类,以区组随机化方法纳入到康复组和对照组,康复组688例,对照组677例,共计1365例.康复组患者除了进行一般的神经内科常规诊疗外,同时予以规范的三级康复治疗,对照组仅给予一般的神经内科常规诊疗.分别于入选时,病后1个月、3个月和6个月末采用改良Barthel指数评定量表进行评测.结果 入选时脑梗死组或脑出血组患者日常生活活动能力分布的差异不存在统计学意义,但是入选后各阶段两组之间差异有统计学意义.患者入选后无论是脑梗死康复组、脑出血康复组还是总体康复组,患者日常生活活动能力测评积分明显优于对照组(P＜0.01).6个月随访治疗后,脑梗死康复组、脑出血康复组和总体康复组患者的日常生活活动能力评分分别改善了55.39分、67.12分和58.60分,而对照组分别改善了37.59分、44.58分和39.43分.与对照组比较,脑梗死康复组多了17.80分,脑出血康复组多了22.54分,总体康复组多了19.17分.此外,康复组在入选后各阶段的积分明显优于对照组,积分增长的趋势明显快于对照组,早期尤为明显.结论 规范三级康复治疗对于脑卒中患者各阶段日常生活活动能力的提高具有明显的促进作用。
Which patients with pre-treated locally advanced or metastatic sarcoma benefit most from trabectedin treatment: First results of a retrospective study of the German Interdisciplinary Sarcoma Group (GISG-14 - ReTraSarc).
Authors: Daniel Pink, Adrian Richter, Dimosthenis Andreou, Stephan Richter, Anne Flörcken, Christoph Deinzer, Bernd Kasper, Gerlinde Egerer, Philipp Ivanyi, Armin Tuchscherer, Torsten Kessler, Markus Schuler, Christian Schmidt, Jeannette Bahr, Till Ittermann, Peter Reichardt
Journal: Journal of Clinical Oncology (2020)

11554 Background: Despite the growing amount of published data regarding the outcomes of sarcoma patients treated with trabectedin, still some questions remain unanswered. The aim of the ReTraSarc trial (NCT03284320) was to evaluate the efficacy and safety of trabectedin in a large German population. Methods: Patients treated between 2007-2018 were retrospectively analyzed. All patients had histologically confirmed soft tissue (STS; n = 478) or bone (BS; n = 31) sarcoma; either metastatic (n = 468) or locally advanced (n = 41) disease, and had received at least one cycle of trabectedin. Based on follow-up data (until October 2019), progression-free survival (PFS) and overall survival (OS) after initiation of trabectedin treatment were estimated according to the Kaplan-Meier method. Results: A total of 509 patents were analyzed. Patients had a mean age of 54 years for STS and 30 years for BS-patients, and 25.4% of them aged &gt; 65 years. Overall, 71.4% of patients had a good performance status (ECOG 0/1), and 37.7% received two prior lines, 28.3% three and 34% received &gt; 3 prior lines of systemic treatment. Patients received a median of 3 cycles (IQR: 2-6 cycles) of trabectedin. Trabectedin resulted in an objective response rate (ORR) of 10% with a 37.4% of disease control rate (DCR). The median PFS and OS were 2.5 months (IQR: 1.4-6.1 months) and 8.2 months (IQR: 3-21 months), respectively. Significantly more patients with liposarcoma (22.1%; 95% CI: 15.2-32.2) were free from progression at 12 months after treatment as compared with patients with leiomyosarcoma (8.5%; 95% CI: 4.8-14.9). More analyses of effectiveness and safety are in progress (e.g. stratified per sarcoma subtypes or therapeutic line) and will be presented. Conclusions: The results of this real-life study, with a large number of patients and long-term follow-up, allow us to better analyze PFS and OS in sarcoma patients treated with trabectedin, given in different treatment lines and after dose modifications and/or cycle delays. Additionally, the results of this study enable us to evaluate the real-life impact of rechallenge with trabectedin in a further therapy line. Clinical trial information: NCT03284320 .
Carboplatin versus cetuximab chemoradiation in cisplatin ineligible locally advanced head and neck squamous cell carcinoma.
Authors: Kannan Thanikachalam, Jayasree Krishnan, Farzan Siddiqui, Haythem Y. Ali, Jawad Sheqwara
Journal: Journal of Clinical Oncology (2020)

e18555 Background: Squamous cell carcinomas (SCC) of Head and neck are associated with tobacco, alcohol use and HPV infection. About 60% of patients with head and neck cancers(HNC) are locally advanced on diagnosis. Concurrent chemoradiation (CCRT) is standard of care in inoperable locally advanced HNC(LA-HNC), high risk adjuvant setting and organ function preservation. While cisplatin (CDDP) is the standard of care for CCRT, alternatives are carboplatin alone or cetuximab alone or carboplatin in combination with 5-FU or paclitaxel CCRT in CDDP ineligible setting. Methods: Patients with LA-HNC (SCC), from 01/01/2013-12/31/2018, who were ineligibile for CDDP CCRT and who received either carboplatin or cetuximab CCRT were included. Patients who received induction chemotherapy and had nasopharynx primary were excluded. 68 patients were analyzed to evaluate outcomes in patients who received carboplatin CCRT and cetuximab CCRT. Progression free survival (PFS) and Overall survival (OS) were calculated by Kaplan Meier analysis with SPSS v26. Results: There was a trend toward improved PFS in CarboRT group among oropharynx HNC patients who were P16 Negative(-ve) (59.5 months(m) vs 37.7 m, p value – 0.069). Among oropharynx HNC patients who were p16 positive, there was no statistically significant difference in PFS among CarboRT vs CetuximabRT (45.8 m vs. 39.77 m, p value – 0.51). OS was favorable towards carboRT in oropharynx SCC p16-ve group (59.5 m vs. 40.97 m, p value – 0.41). There was no difference in OS in p16+ve Oropharynx SCC group, who received CarboRT and CetuximabRT (45.74 vs. 45.94 m, p value – 0.77). When patients were analyzed regardless of their p16 status, site or stage, patients who received CarboRT had a higher OS at 56.30 m (95% CI 45.10-67.50%) vs. 38.11 m (95% CI 28.84-47.38%) among patients who received CetuximabRT (p value-0.048). Though PFS clinically favored carboRT group, when compared to CetuximabRT (55.43 m vs. 36.75 m), it was not statistically significant (p value – 0.10). Conclusions: In our analysis, patients who received single agent carboplatin CCRT had higher OS when compared to cetuximab CCRT. Though other outcomes favored carboplatinRT including PFS among entire group and p16-ve group, OS in p16-ve patients, it was not statistically significant, which is likely due to low power. Based on our analysis, for LA-HNC, carboplatin CCRT should be favored over cetuximab CCRT for patients ineligible for CDDP, particularly in P-16 -ve disease. Further randomized clinical trials can shed more data in this reduced intensity regimen.